Grifols A : Appealing valuation on normalised earnings
>Trading update confirms plasma recovery and better margins in Q1 2022 - Grifols has sent a trading update with some indications on Q1 sales and EBITDA. The company is confirming that plasma collections reported 16% growth during the first 17 weeks of the year v. 2021 and +9% sequentially. Group sales grew by mid-to-high single digit y-o-y in Q1 2022 (low-single-digit at cc vs -10% growth ex forex in H2 2021), above our flat sales estimate. According to Grifols, the B...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.